Global /United States /Healthcare /Drug Manufacturers - General /ATXI

Avenue Therapeutics, Inc.

ATXI

• OTCMKTS: ATXI • Delayed

0.5500USD 0%

As of 13 June 2026, Avenue Therapeutics, Inc. has a market cap of $1.81M USD, ranking #47421 globally and #6029 in the United States. It ranks #4205 in the Healthcare sector, and #1330 in the Drug Manufacturers - General industry.

Global Rank

47421

Country Rank

6029

Sector Rank

4205

Industry Rank

1330

Key Stats

Market Cap

$1.81MUSD

Enterprise Value

-$1.04MUSD

Revenue (TTM)

$1.4MUSD

Net Income (TTM)

-$2.91MUSD

Profit Margin

-207%

PS Ratio

1.3

PB Ratio

1.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Alexandra MacLean open_in_new

Employees

Founded

2015

Website

avenuetx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	5.8%	90%	88%	-23%	-19%	118%	-99%	-100%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	ATXI Avenue Therapeutics Inc ISIN: US05360L4032 Shares Out.: Shares Outstanding: 3.295M¹ Shares Float: 2.85M² TV: TradingView: OTC: ATXI SA: Stock Analysis: OTC: ATXI YF: Yahoo Finance: ATXI GF: Google Finance: OTCMKTS: ATXI BA: Barron's: ATXI MS: Morningstar: PINX: ATXI	0.5500 USD	TV: TradingView: OTC: ATXI SA: Stock Analysis: OTC: ATXI YF: Yahoo Finance: ATXI GF: Google Finance: OTCMKTS: ATXI BA: Barron's: ATXI MS: Morningstar: PINX: ATXI

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 42M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 30M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 20M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 15M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 8M%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 6M%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 18M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 16M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 15M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 10M%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 6M%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 6M%	14.6	United Kingdom

chevron_leftBack